What do the screening trials really tell us and where do we go from here?

Urologic Clinics of North America

Volumn 41, Issue 2, 2014, Pages 223-228

  Etzioni, Ruth D ^a   Thompson, Ian M ^b  

^a USA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Clinical trials; Mass screening; Prostate cancer; Prostate specific antigen; Public health policy; Simulation modeling

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; DIGITAL RECTAL EXAMINATION; DISEASE SURVEILLANCE; FALSE POSITIVE RESULT; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS;

CLINICAL TRIALS; MASS SCREENING; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; PUBLIC HEALTH POLICY; SIMULATION MODELING;

CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84898425316     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2014.01.002     Document Type: Review

References (28)

1. Mariotto A., Etzioni R., Krapcho M., et al. Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer 2007, 109(9):1877-1886.
2. Moyer V.A., on behalf of the USPSTF Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012, 157(2):120-134.
3. Wolf A.M., Wender R.C., Etzioni R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010, 60(2):70-98.
4. Association AU. Early detection of prostate cancer: AUA guideline. 2013. Available at: Accessed February 10, 2014. http://www.auanet.org/education/guidelines/prostate-cancer-detection.cfm.
5. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360(13):1310-1319.
6. Andriole G.L., Crawford E.D., Grubb R.L., et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104:1-8.
7. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13):1320-1328.
8. Schröder F.H., Hugosson J., Roobol M.J., et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366(11):981-990.
9. Hanley J.A. Mortality reductions produced by sustained prostate cancer screening have been underestimated. J Med Screen 2010, 17(3):147-151.
10. Hanley J.A. Measuring mortality reductions in cancer screening trials. Epidemiol Rev 2011, 33(1):36-45.
11. Gulati R., Mariotto A.B., Chen S., et al. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol 2011, 64(12):1412-1417.
12. Pinsky P.F., Andriole G.L., Kramer B.S., et al. Prostate biopsy following a positive screen in the Prostate, Lung, Colorectal and Ovarian cancer screening trial. J Urol 2005, 173(3):746-750. [discussion: 50-1].
13. Pinsky P.F., Black A., Kramer B.S., et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Clin Trials 2010, 7(4):303-311.
14. Gulati R., Tsodikov A., Wever E.M., et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012, 23(6):827-835.
15. Grubb R.L., Pinsky P.F., Greenlee R.T., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008, 102(11):1524-1530.
16. Schröder F.H., Denis L.J., Roobol M., et al. The story of the European randomized study of screening for prostate cancer. BJU Int 2003, 92(Suppl 2):1-13.
17. Ciatto S., Zappa M., Villers A., et al. Contamination by opportunistic screening in the European randomized study of prostate cancer screening. BJU Int 2003, 92(Suppl 2):97-100.
18. Roobol M.J., Kerkhof M., Schröder F.H., et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009, 56(4):584-591.
19. Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11(8):725-732.
20. Kilpelainen T.P., Tammela T.L., Malila N., et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013, 105(10):719-725.
21. Roobol M.J., Kranse R., Bangma C.H., et al. Screening for prostate cancer: results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2013, 64(4):530-539.
22. Loeb S., Vonesh E.F., Metter E.J., et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?. J Clin Oncol 2011, 29(4):464-467.
23. Etzioni R., Gulati R., Cooperberg M.R., et al. Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and prostate cancer screening. Med Care 2013, 51(4):295-300.
24. Heijnsdijk E.A., Wever E.M., Auvinen A., et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012, 367(7):595-605.
25. Gulati R., Gore J.L., Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013, 158(3):145-153.
26. Vickers A.J., Ulmert D., Sjoberg D.D., et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013, 346:f2023.
27. Sox H.C. Quality of life and guidelines for PSA screening. N Engl J Med 2012, 367(7):669-671.
28. Carter H.B., Albertsen P.C., Barry M.J., et al. Early detection of prostate cancer: AUA guideline. J Urol 2013, 190(2):419-426.